Medical 21

St. Jude Medical founder Manny Villafaña draws on his experience developing a new medical device to offer insights for innovators in the medical device sector. His approach emphasizes real-world clinical needs and patient-centered design principles. Villafaña highlights how early surgeon feedback shaped the device’s development trajectory.

Oct 2026Medical Design and OutsourcingNews article

Manny Villafaña and Medical 21 introduce a regenerative artificial artery designed for coronary artery bypass grafting (CABG). The device represents Villafaña’s largest project to date, following his past sales of medical device companies totaling $67 billion. This innovation aims to address limitations in current vascular graft solutions.

Aug 2026Medical Design and OutsourcingNews article

Medical 21, a Minneapolis-based developer of synthetic regenerative grafts for coronary bypass surgery, files for a $25 million initial public offering. The company plans to raise capital by selling 2.3 million shares at a proposed price range of $10 to $... per share. The filing marks a key step toward public market entry for its regenerative medical technology.

Feb 2026Renaissance CapitalNews article

Medical 21 has begun its first-in-human clinical trial of the **Maverics graft**, a regenerative small-diameter coronary bypass graft, under the **MAVERICS study**. The trial, approved by Spain’s EU MDR, marks the first multicentre test of this novel device. The graft aims to address limitations in traditional bypass procedures by leveraging regenerative technology.

Dec 2025Cardiovascular NewsNews article